Tibet Duo Rui Pharmaceutical Co., Ltd. (SHE:301075)

Market Cap	3.83B +37.1%
Revenue (ttm)	137.16M -43.0%
Net Income	-100.54M
EPS	-1.27
Shares Out	78.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,203,800
Open	50.14
Previous Close	48.28
Day's Range	46.49 - 50.14
52-Week Range	34.20 - 98.29
Beta	0.59
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About SHE:301075

Tibet Duo Rui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical formulations, chemical intermediates, and peptide APIs in China. It offers fluid therapy, anesthesiology medication, analgesic medication, and first-aid medication products, as well as multiple electrolytes injection; sodium acetate ringer's injection. Tibet Duo Rui Pharmaceutical Co., Ltd. was founded in 2005 and is headquartered in Tibet, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 461
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301075

Financial Performance

In 2025, SHE:301075's revenue was 154.18 million, a decrease of -35.93% compared to the previous year's 240.63 million. Losses were -102.17 million, 63.0% more than in 2024.

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Jul 30, 2026

Data Sources Report a data error